A Phase 1, 2-Part, Multicentre, Open-Label, 3 Arm Study to Determine the Effect of Enasidenib (Cc-90007) On the Pharmacokinetics of Single Doses of Caffeine, Dextromethorphan, Flurbiprofen, Midazolam, Omeprazole, Digoxin, Rosuvastatin, And Pioglitazone in Subjects with Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation.

Project: Research

Project Details

Project Description

NMA HREC Ref Number: HREC/18/Austin/183 (ERM Project ID: 40362)
NMA SSA Reference Number: SSA/40362/MonH-2018-152948
Monash Health Ref: RES-18-0000-603X
Effective start/end date16/11/1815/11/23


  • phase 1 and 2 study
  • clinical trial
  • leukemia
  • treatment efficacy